Question-and-Answer Session
[Operator Instructions]. Your first question comes from the line of Greg Gilbert with Merrill Lynch.
Gregory Gilbert - Merrill Lynch
I have a few. Firstly, on new products... some $67 million in new products in the quarter, which I think compared to $75 million last quarter and $92 million, the quarter before that, were there any significant products that rolled out of that number in the past couple of quarters? Do that make sense?
Joseph C. Papa - Chairman and Chief Executive Officer
Most of the products that are in are similar products. It was in a major and there is couple of smaller products, classical products that have rolled out. But they were in a major contribution to some of the smaller cough-cold products that have been launched in prior years.
Gregory Gilbert - Merrill Lynch
So, would you talk that step down two quarters in a row to sort of initial stocking of the two big products followed by some seasonality or any more context you can provide there?
Joseph C. Papa - Chairman and Chief Executive Officer
Yes, the primary area is really the latter part of your comment, the seasonality issue, we expect obviously Cetirizine to continue to go up and especially as we reach additional allergy seasons et cetera. So, I think it's really more just seasonality with little bit of change in some of the products in the category, but that's really the primary areas. Obviously, we are still delighted, because this is a record for us on new products during the quarter.
Gregory Gilbert - Merrill Lynch
And then on Omeprazole specifically, Joe, I know IRI doesn't capture everything. IRI suggest that the share growth has moderated a fair amount. Can you comment based on your more comprehensive data that you have at Perrigo on the trend for Omeprazole there?
Joseph C. Papa - Chairman and Chief Executive Officer
Yes, I think it is... the data that we look at is IRI, plus we have some additional customer-specific data that we have. As we look at that combination of that data Greg, we still feel we are absolutely on track to hit the numbers that we talked about $150 million to $200 million. On balance, we clearly see moderations in that based on a weekly basis and a monthly basis. And it really depends on the number of promotions that occur in any of our individual customers. We see as we do more promotions with customer A that their share will go up in any given week or quarter or so. What we are looking to is continue to drive those promotions. We are happy with the results. We still believe we're on track to reach the $150 million to $200 million number that we talked about, really going on now almost a year now.
- To read the full transcript on Seeking Alpha, click here »
